Advertisement
"With the initiation of this study, all three of Omeros' currentPharmacoSurgery product candidates are now in the clinic," said Gregory A.Demopulos, M.D., Chairman and CEO of Omeros. "Each of the two agents in OMS302is currently used individually and perioperatively during eye surgery. OMS302combines these two agents and their pharmacologic activities into a singleproprietary product candidate. With approximately three million cataractprocedures performed annually in the U.S. alone, OMS302 is designed to addressa large and growing market."
Advertisement
The Phase 1/Phase 2 trial is a randomized, double-blind,vehicle-controlled and parallel-assigned study evaluating the effects ofOMS302 on dilation of the pupil during cataract surgery and on pain,discomfort and inflammation following the procedure. OMS302 is added tostandard irrigation solutions used in ophthalmologic surgery and is delivereddirectly to the eye during the operation.
PharmacoSurgery(TM) product candidates are proprietary combinations oftherapeutic agents designed to act simultaneously at multiple discrete targetsto preemptively block the molecular-signaling and biochemical cascade causedby surgical trauma and to provide clinical benefits both during and aftersurgery. The lead product candidate in the PharmacoSurgery(TM) platform isOMS103HP, which is currently in two Phase 3 clinical programs evaluating itssafety and ability to improve postoperative joint function and reduce painfollowing arthroscopic surgery. The urological PharmacoSurgery(TM) productcandidate OMS201, currently in a fully enrolled Phase 1 clinical study, isdesigned to inhibit surgically induced inflammation, pain and smooth musclespasm, thereby facilitating uroendoscopy and reducing postoperative frequency,urgency and discomfort.
About Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company committedto discovering, developing and commercializing products focused oninflammation and disorders of the central nervous system. Omeros' mostclinically advanced product candidates are derived from its proprietaryPharmacoSurgery(TM) platform designed to improve clinical outcomes of patientsundergoing arthroscopic, ophthalmological, urological and other surgical andmedical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinicaldevelopment programs, and its lead product candidate, OMS103HP, is beingevaluated in Phase 3 clinical trials for use during arthroscopic surgery toimprove postoperative joint function and reduce postoperative pain. Omeros isalso building a diverse pipeline of pre-clinical programs targetinginflammation and central nervous system disorders. For more information onOmeros, visit the Company's Web site at www.omeros.com.
SOURCE Omeros Corporation
